Related Experiment Video
Updated: Jun 16, 2026
Preterm EEG: A Multimodal Neurophysiological Protocol
Published on: February 18, 2012
Multi-modal screening for synergistic neuroprotection of mild extremely preterm brain injury
Zheyu Ruby Jin1, Kylie A Corry2, Olivia C Brandon2
1Department of Chemical Engineering University of Washington Seattle Washington USA.
Insights
Combining azithromycin and erythropoietin offers synergistic neuroprotection against preterm brain injury. This combination therapy shows promise for treating neurodevelopmental deficits in preterm infants.
Area of Science:
- Neuroscience
- Developmental Biology
- Pharmacology
Background:
- Preterm brain injury impacts white and gray matter, leading to neurodevelopmental issues like cerebral palsy.
- Heterogeneous brain responses necessitate combination therapies for effective neuroprotection.
Purpose of the Study:
- To investigate the neuroprotective potential of azithromycin and erythropoietin, alone and in combination, in a novel ferret brain slice model.
- To elucidate the molecular mechanisms underlying synergistic neuroprotection.
Main Methods:
- Development of an organotypic whole hemisphere (OWH) slice culture model from gyrencephalic ferret brains.
- Assessment of regional and global responses using cell death quantification, advanced microglia analysis, and digital transcriptomics.
- Evaluation of azithromycin (Az) and erythropoietin (Epo) treatment effects, both individually and in combination (Az*Epo).
Main Results:
- Neither azithromycin nor erythropoietin alone provided significant neuroprotection.
- The combination of azithromycin and erythropoietin (Az*Epo) demonstrated synergistic neuroprotection globally and regionally.
- Az*Epo therapy modulated transcriptomic pathways, enhancing neurogenesis and neuroplasticity while reducing inflammation and cell death.
Conclusions:
- The ferret OWH slice culture model is a valuable platform for preclinical assessment of combination therapies for preterm brain injury.
- Synergistic neuroprotection by Az*Epo offers a promising therapeutic strategy for mitigating the effects of preterm brain injury and associated neurodevelopmental deficits.
Abstract:
Preterm brain injury affects both white and gray matter, including altered cortical development and gyrification, with associated neurodevelopmental sequelae such as cerebral palsy and learning deficits. The preterm brain also displays regionally heterogeneous responses to both injury and treatment, suggesting that drug combinations may be needed to provide global neuroprotection. We developed an extremely preterm-equivalent organotypic whole hemisphere (OWH) slice culture mild injury model using the gyrencephalic ferret brain to probe treatment mechanisms of promising therapeutic agents and their combination. Regional and global responses to injury and treatment were assessed by cell death quantification, machine learning-augmented morphological microglia assessments, and digital transcriptomics. Using two promising therapeutic agents, azithromycin (Az) and erythropoietin (Epo), we show minimal neuroprotection by either therapy alone, but evidence of synergistic neuroprotection by Az*Epo both globally and regionally. This effect of Az*Epo involved augmentation of transcriptomic responses to injury related to neurogenesis and neuroplasticity and downregulation of transcripts involved in cytokine production, inflammation, and cell death. With the increasing need to develop therapies for extremely preterm brain injury, the ferret OWH slice culture model provides a high-throughput platform to examine combinations of therapeutics as part of a preclinical therapeutic pipeline.
